Outcome Measures for Psoriasis Severity: A Report from the GRAPPA 2012 Annual Meeting

REFERENCES

1. 1.↵
   1. Gladman DD,
   2. Helliwell PS,
   3. Khraishi M,
   4. Callis Duffin K,
   5. Mease PJ

   . Dermatology screening tools: Project update from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1425–7.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gottlieb AB,
   2. Armstrong AW

   . Psoriasis outcome measures: A report from the GRAPPA 2012 annual meeting. J Rheumatol 2013;40:1428–33.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Spuls PI,
   2. Lecluse LL,
   3. Poulsen ML,
   4. Bos JD,
   5. Stern RS,
   6. Nijsten T

   . How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933–43.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fredriksson T,
   2. Pettersson U

   . Severe psoriasis — oral therapy with a new retinoid. Dermatologica 1978;157:238–44.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Naldi L,
   2. Svensson A,
   3. Zenoni D,
   4. Diepgen T,
   5. Elsner P,
   6. Grob JJ,
   7. et al.

   Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: Update of the EDEN Psoriasis Survey 2001–2006. Br J Dermatol 2010;162:384–9.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Robinson A,
   2. Kardos M,
   3. Kimball AB

   . Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369–75.

   OpenUrlCrossRefPubMed
7. 7.↵
   Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting 1998: Food and Drug Administration, Department of Health and Human Services, Public Health Service, March 20, 1998. Washington, DC: Miller Reporting Company, Inc; 1998.
8. 8.↵
   1. Langley RG,
   2. Ellis CN

   . Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004;51:563–9.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Tugwell P,
   2. Boers M,
   3. Brooks P,
   4. Simon L,
   5. Strand V,
   6. Idzerda L

   . OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.

   OpenUrlCrossRefPubMed
10. 10.↵
    OMERACT — International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. [updated 2013; cited 18 March 2013]; Available from: www.omeract.org